Bristol-Myers Squibb Company (BMY)
California Public Employees Retirement System Cuts Stock Position in Bristol Myers Squibb Company $BMY
California Public Employees Retirement System trimmed its stake in shares of Bristol Myers Squibb Company (NYSE: BMY) by 8.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,645,956 shares of the biopharmaceutical company's stock after selling
44 Wealth Management LLC Raises Holdings in Bristol Myers Squibb Company $BMY
44 Wealth Management LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 16.2% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 66,562 shares of the biopharmaceutical company's stock after acquiring an additional 9,257 shares during the quarter. Bristol Myers
Glenmede Investment Management LP Purchases 252,666 Shares of Bristol Myers Squibb Company $BMY
Glenmede Investment Management LP grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 31.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,065,333 shares of the biopharmaceutical company's stock after acquiring an additional 252,666 shares during the quarter. Glenmede
Is Bristol Myers' Deep Pipeline the Key to Future Growth?
BMY highlights a deep pipeline with multiple late-stage candidates and registrational data expected in 2026, reinforcing confidence in its next-gen CELMoD program.
BMY Advances CELMoD Program With Positive Phase III Results
BMY reports positive phase III SUCCESSOR-2 data as mezigdomide combo improves progression-free survival in relapsed multiple myeloma, boosting CELMoD program.
Virtus Large Cap Growth SMA Q4 2025 Portfolio Review
The Silvant Large Cap Growth SMA returned +2.69% (gross)/+1.94% (net) for the quarter, outperforming the Russell 1000 Growth Index's return of +1.12%. Eli Lilly and Alphabet were among the top stock contributors to relative performance. Royal Caribbean and O'Reilly Automotive were among the largest stock detractors from relative performance.
BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis
Bristol Myers wins FDA approval to expand Sotyktu for psoriatic arthritis after strong POETYK study data, adding a new indication for the TYK2 inhibitor.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Bristol Myers Squibb (BMY) closed at $60.74, marking a -2.55% move from the previous day.
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?
Reblozyl tops $2.3B in annualized sales, emerging as a key drug for Bristol Myers as demand rises in MDS-related anemia and new study data support expansion.
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock?
Bristol Myers rides growth brands like Opdivo and Reblozyl to offset generics, with pipeline catalysts and cost cuts shaping its next phase.
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
